Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Lundbeckfonden Ventures

Lundbeckfonden Ventures

Lundbeckfonden Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by Lundbeck Foundation

Lundbeckfonden Ventures is an evergreen venture fund that was founded in 2009 and is entirely owned by the Lundbeck Foundation. It invests in life science companies and focuses on projects and companies close to or in clinical development.

Lundbeckfonden Ventures is a venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.

The Lundbeck Foundation

The Lundbeck Foundation is a Danish foundation that was founded in 1954 by Grete Lundbeck and is worth over DKK 60 billion. They award research grants of around DKK 500 million each year to Danish-based, biomedical sciences research, primarily in the field of brain research.


Lundbeckfonden invests in biotechnology and medical companies worldwide with annual investments of 350 to 400 million Danish kroner.The company invests at early and late venture stage.

Investments include Amplyx Pharmaceuticals, Cydan and Enterome Bioscience and exits include Spero Therapeutics, Acacia Pharma and Ziarco.

Lundbeckfonden Ventures is an evergreen life science venture capital firm in Copenhagen that invests in early and late stage ventures. Established in the autumn of 2009 and wholly owned by Lundbeck Foundation, it offers flexible and long-term investments. It typically invests in Series B, Series A, Series C, and in post-IPO equity. Its portfolio companies include Spero Therapeutics, SANIFIT, Reneo Pharmaceuticals, Aura Biosciences, River Vision Development, Vtesse, Ziarco, Celladon and Asante Solutions.

Since 2009, the company has invested in 31 life science companies in the US and Europe, and have an active portfolio of about 20 companies representing a wide range of therapeutic areas. It invests around DKK 350 to 400 million annually.



Invested in


Funding Rounds Participated In

Further Resources



March 22, 2021
Christine Hall
May 19, 2020
Crunchbase News
Biotech company Amplyx Pharmaceuticals increases its Series C to more than $90 million, aimed at advancing two therapies toward clinical development.


Golden logo
By using this site, you agree to our Terms & Conditions.